AstraZeneca’s top-selling Tagrisso drug was approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on May 28.

AstraZeneca Plc’s Imfinzi was approved in the European Union to treat an aggressive form of lung cancer in previously untreated adult patients.

As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.

Emeryville, California-based Zogenix announced positive topline data from the company’s Phase III trial of Fintepla (fenfluramine) in Lennox-Gastaut Syndrome.

Bristol-Myers Squibb withdrew the company’s application in the European Union for the combination of Opdivo and Yervoy for the treatment of advanced non-small cell lung cancer (NSCLC) based on data from CheckMate -227.

Bayer won an endorsement from the European Union’s drug regulator for the company’s prostate cancer drug darolutamide, putting the medicine on track for approval to take on rival products from Pfizer and Johnson & Johnson.

A panel of the European medicines regulator recommended approving Novo Nordisk’s new diabetes pill Rybelsus, further boosting prospects for the Danish drugmaker with the company’s first-of-a-kind, non-injectable treatment.

Pharma companies from across the globe provide updates on their pipelines and business.

The U.S. Food and Drug Administration approved drugmaker Merck & Co.’s Ebola vaccine Ervebo, the first FDA-authorized vaccine against the deadly virus.

The European Commission granted marketing authorization to Amgen and UCB for Evenity (romosozumab) for treating severe osteoporosis in postmenopausal women at high risk of fracture.